Browsing Modes for Business Users

Bevacizumab antibody | AbD16748_hIgG1

Human anti Bevacizumab:HRP

Product Type
Monoclonal Antibody

Product Code Applications Pack Size List Price Your Price Qty
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
E 0.1 mg loader
List Price Your Price

Human Anti-Bevacizumab Antibody, clone AbD16748_IgG1 is a paratope-specific, recombinant anti-idiotypic antibody that specifically recognizes the humanized monoclonal antibody drug bevacizumab and inhibits the binding of the drug to its target, vascular endothelial growth factor A (VEGF-A). The antibody can be used to measure the levels of bevacizumab and biosimilars in serum from patients.

A pair of anti-bevacizumab antibodies can be used to develop a pharmacokinetic (PK) bridging ELISA to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Bevacizumab Antibody in monovalent Fab format, clone AbD17976 (HCA182) as the capture antibody.

Bevacizumab (reference product branded as Avastin) is a humanized monoclonal antibody (IgG1/kappa) that inhibits angiogenesis by binding to VEGF-A. VEGF-A is a potent stimulator of angiogenesis of both normal and cancerous cells, and acts as a regulator of vasculogenesis. Bevacizumab is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.

View a summary of all Anti-Bevacizumab Antibodies.
20th Anniversary

Product Form
Human IgG1 antibody (kappa light chain) selected from the HuCAL phage display library and expressed in a human cell line.
Purified IgG prepared by affinity chromatography on Protein A.
Buffer Solution
Phosphate buffered saline.
Preservative Stabilisers
0.01% Thiomersal.
The monovalent intrinsic affinity of this antibodyis KD=2.1nM as measured by real time, label-free molecular interaction analysis on immobilized Bevacizumab.
Approx. Protein Concentrations
Total protein concentration 1.0 mg/ml.
For research purposes only.
12 months from date of despatch.
This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See for details.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

This product is shipped frozen.
When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual.
This product may be used in a direct ELISA or as a detection reagent in a sandwich ELISA together with HCA182 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug.

Description Product Code Applications Pack Size List Price Your Price Quantity
Human anti Bevacizumab HCA182 E 0.1 mg loader
List Price Your Price
Description Human anti Bevacizumab

References for Bevacizumab antibody

  1. Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
    US Patent Application US20170315118A1
  2. Lallemand, C. et al. (2020) Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma.
    Front Immunol. 11: 515556.



155380 163160 INN1709 INN1806

If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.

View more products with BEVACIZUMAB specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

Please note